Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the appointment of Dr. William E Haskins as Director of R&D, Bioanalytical Chemistry.
Catalent Pharma Solutions and Zumutor Biologics Inc. today announced a successful research study, combining Catalent’s proprietary GPEx® technology and Zumutor’s fucose knockout platform, to create new and more efficacious antibodies.
Catalent Pharma Solutions today announced that it is extending its OptiForm® Solution Suite technology platform to introduce rapid screening of macromolecules’ suitability for non-invasive drug delivery.
Catalent today announced that Dr. David Rabuka, Global Head of R&D, Chemical Biology, and Dr. Gregory T Bleck, Global Head of R&D, Biologics, will be participating at the Protein and Antibody Engineering Summit.
The Catalent Applied Drug Delivery Institute today announced that it will hold a one day symposium, entitled “Advances in Biologics Development and Delivery,” at the University of California, San Francisco (UCSF), Mission Bay Campus, San Francisco, CA., on Thursday, March 24, 2016.
Catalent today announced that Dr. Gregory Bleck, Global Head of R&D, Catalent Biologics, will be presenting at the upcoming BioProcess International West Conference, to be held at the Oakland Marriott City Center Hotel, Oakland, CA, on March 14th – 17th, 2016.
